American Cryostem (American Cryostem) EBIT per Share : $-0.07 (TTM As of Jun. 2022)

View and export this data going back to 2010. Start your Free Trial

What is American Cryostem EBIT per Share?

American Cryostem's EBIT per Share for the three months ended in Jun. 2022 was $-0.01. Its EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 was $-0.07.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for American Cryostem's EBIT per Share or its related term are showing as below:

CRYO's 3-Year EBIT Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 3.5
* Ranked among companies with meaningful 3-Year EBIT Growth Rate only.

American Cryostem's EBIT for the three months ended in Jun. 2022 was $-0.38 Mil.

American Cryostem EBIT per Share Historical Data

The historical data trend for American Cryostem's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

American Cryostem EBIT per Share Chart

American Cryostem Annual Data

Trend

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

EBIT per Share

Get a 7-Day Free Trial

-0.03

-0.02

-0.05

American Cryostem Quarterly Data
	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22
EBIT per Share	Get a 7-Day Free Trial															-0.01	-0.03	-0.01	-0.02	-0.01

American Cryostem EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

American Cryostem's EBIT per Share for the fiscal year that ended in Sep. 2021 is calculated as

	EBIT per Share		(A: Sep. 2021 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-2.776	/	60.342
=	-0.05

American Cryostem's EBIT per Share for the quarter that ended in Jun. 2022 is calculated as

	EBIT per Share		(Q: Jun. 2022 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-0.377	/	43.995
=	-0.01

EBIT per Share for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.07

American Cryostem (OTCPK:CRYO) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

American Cryostem EBIT per Share Related Terms

Thank you for viewing the detailed overview of American Cryostem's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

American Cryostem (American Cryostem) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » American Cryostem Corp (OTCPK:CRYO) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Meridian Road, Suite 5, Eatontown, NJ, USA, 07724

Website

http://www.americancryostem.com

American Cryostem Corp is a biotechnology company which standardizes adipose tissue-derived technologies (Adult Stem Cells) for the fields of Regenerative and Personalized Medicine. The company acts as an innovator of adipose tissue and stem cell platform technologies. It provides the clinical grade, adipose tissue and adult stem cell collection, processing, and cryo-preservation technology, providing first-in-class cellular therapy products and services for patients, physicians and researchers based on the transformative science of Regenerative and Personalized Medicine.

Executives

John S Arnone	director, officer: Chairman	111 GREAT NECK RD, GREAT NECK NY 11021
Anthony Francis Dudzinski	director, officer: COO	188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Acs Global, Inc.	10 percent owner	188 E. BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Christopher Joseph Neill	10 percent owner	188 EAST BERGEN PLACE, SUITE 204, RED BANK NJ 07701
Hector Medina	director, 10 percent owner, officer: President and Director	1206 STAGECOACH TRAIL LOOP, CHULA VISTA CA 91915